DCU Spin-out BreathDX launches breakthrough ammonia detection device
02 November 2017
New breath ammonia measurement technology will be unveiled at the world’s largest event for the medical sector, MEDICA 2017.
BreathDX will launch its two new breath ammonia measurement devices to the market at this year’s MEDICA conference, held November 13-16, in Dusseldorf, Germany. The AmBeR® and AmBeR® Clinical devices measure highly accurate ammonia levels in just eight breaths and are the most viable, cost-effective alternative to blood-based tests.
Ammonia is an important chemical in the breath that is linked with a range of known and likely conditions from stomach ulcers (eg H. pylori) to metabolic issues and hepatic encephalopathy. In the medical industry, breath ammonia monitoring is rare due to the cost and complexity associated with the detection instruments.
AmBeR® and AmBeR Clinical® make it easy to test more frequently and can be used in all clinical environments, or in the home for patients who are required to constantly monitor their blood ammonia levels. Clinical evaluations have now commenced in a number of UK hospitals to demonstrate that ammonia measurements have the same level of accuracy as standard blood-based tests.
The point of care AmBeR® devices use a custom designed impedance circuit and airflow module. The devices incorporate inexpensive disposable printed sensors based on nanotechnology to provide the fast, accurate and quality analysis. The specific patented technology in the devices was developed by Professor Tony Killard during his time at the Biomedical Diagnostics Institute at Dublin City University.
The two devices are AmBeR®, which can be used in both homes and hospital as a noneedle solution for ammonia testing, and AmBeR® Clinical, suitable for R&D or where large volumes of patients and sampling regimes are required. AmBeR® Clinical has the same functionality as AmBeR®, as well as having greater control and can be customised through an external software interface.
BreathDX currently has devices in clinical evaluations, will shortly install AmBeR® systems in patients’ homes and has secured significant investment from the National Institute for Health Research (NIHR). The company also has a worldwide licence agreement with Dublin City University (DCU) for access to the innovative AmBeR® technology. DCU has earned a strong reputation for enterprise through identifying innovations like AmBeR® and recognising their commercial potential.
Killard, Chief Technology Officer at BreathDX said: “After more than a decade of development and significant research investment, we are delighted to bring AmBeR® to market. MEDICA 2017 offers the perfect platform to launch the devices. As Europe’s most comprehensive medical trade fair, it draws medical professionals from around the globe and is renowned for focusing on revolutionary ideas in medical care.
“We’ve already received a very positive response to AmBeR from medics, researchers and industry bodies, who have welcomed its ability to allow patients easy every day testing and help companies perform critical research.”
About BreathDX – Founded by Professor Tony Killard, BreathDX is a UK-based company located in the growing bio-medical hub of South West England. Professor Killard is the principal inventor of AmBeR. He is Professor of Biomedical Sciences at the University of the West of England and Adjunct Professor at Dublin City University where the technology was developed. He has dedicated a significant part of his work to designing and developing the device. The highly experienced BreathDX team has already secured UK device-to-market funding, and AmBeR is being brought to market with UK funding of more than €1 million. Dublin City University licensed the AmBeR technology to BreathDX in August 2015 and also holds an equity stake in the company.
About AmBeR - AmBeR is a new ammonia in-breath measurement device. Designed to diagnose and manage a range of conditions it offers a simple, quick and accurate alternative to blood tests. AmBeR has the potential to revolutionise the standard of care for patients and their families, and at the same time provides the ultimate cost effective solution for effective disease management for healthcare providers.
Contact – email@example.com